
Pharma boosts lobby spending in first quarter of 2019
pharmafile | April 24, 2019 | News story | Research and Development |Â Â PhRMA, Trump, USA, congress, lobbying, lobbyists, pharmaÂ
The Pharmaceutical Research and Manufacturers of America (PhRMA) trade lobbyists have spent near record levels on lobbying in the first three months of 2019.
According to disclosures filed to Congress, the US lobby group spent $9.91 million in the first quarter of 2019.
The figures show a moer than 50% increase on the final quarter of 2018, as spending increased from $6.03 million in the last three months of last year. In total PhRMA spent a record $27.5 million on lobbying in 2018.
Meanwhile AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Eli Lilly and Genentech were all shown to have increased spending on lobbying in the first three months of 2019.
While AstraZeneca were shown to have spent $1 million on lobbying in the first quarter of 2019, compared to $600,000 in the first quarter of last year, Bristol-Myers Squibb increased spending to $1.2 million from $800,000 last year.
US firms J&J and Eli Lilly boosted lobby money to $1.4 million while Genentech came out on top spending $3 million in the first quarter of 2019, compared to $1.7 million over the same period last year.
The extra spending comes amid the Trump administration’s pricing plan, which sets out to lower the price of drugs through price transparency and new rules for generic drugs. Meanwhile Congress has ramped up the pressure on price hiking firms.
Louis Goss
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …






